Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Plus R-CHOP for High-risk GCB-subtype DLBCL
NCT05422066Phase 2Recruiting
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Complete Response Rate at 18 months. Started Jul 2022; status: recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05422066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05422066.